Phase 1b/2 Study of Onvansertib + Paclitaxel in Triple-Negative Breast Cancer (TNBC)
Status:
Not yet recruiting
Trial end date:
2029-02-15
Target enrollment:
Participant gender:
Summary
This research is being done to evaluate the safety and effectiveness of Onvansertib in
combination with Paclitaxel in triple-negative breast cancer (TNBC) that has spread to other
parts of the body.
The names of the study interventions involved in this study are:
- Onvansertib
- Paclitaxel